OVERLAND PARK, Kan.—July 24 2024—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early-phase clinical trials, is pleased to announce "Accelerating Clinical & Drug Development Timelines with AI," an exclusive...
OVERLAND PARK, Kan.—May 08 2024—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned...
OVERLAND PARK, Kan.—March 13 2024—Dr. Vince Clinical Research (DVCR), a contract research organization specializing in early phase trials, announced the first dosing in a Phase II multi-center trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is...
OVERLAND PARK, Kan.--Dec 12 2023--Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO) announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships and more...
OVERLAND PARK, Kan.–September 06 2023–Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom...
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
OVERLAND PARK, Kan. - August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose...
OVERLAND PARK, Kan. - June 27, 2023 – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes certifications. Considering...
OVERLAND PARK, KS - January 10 2023 - Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending dose (MAD) study for an...